See more : The Clorox Company (CLX) Income Statement Analysis – Financial Results
Complete financial analysis of TaiDoc Technology Corporation (4736.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TaiDoc Technology Corporation, a leading company in the Healthcare industry within the Healthcare sector.
- Zenrin Co., Ltd. (9474.T) Income Statement Analysis – Financial Results
- Purepoint Uranium Group Inc. (PTUUF) Income Statement Analysis – Financial Results
- Meituan (3690.HK) Income Statement Analysis – Financial Results
- ECN Capital Corp. (ECN-PC.TO) Income Statement Analysis – Financial Results
- Hess Corporation (AHC.DE) Income Statement Analysis – Financial Results
TaiDoc Technology Corporation (4736.TW)
About TaiDoc Technology Corporation
TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. It also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, the company offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. Further, the company provides various applications, including MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and USB adapter driver. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 4.81B | 9.63B | 6.49B | 5.90B | 0.00 |
| Cost of Revenue | 2.73B | 3.98B | 3.28B | 2.95B | 0.00 |
| Gross Profit | 2.07B | 5.65B | 3.21B | 2.95B | 0.00 |
| Gross Profit Ratio | 43.12% | 58.65% | 49.42% | 49.99% | 0.00% |
| Research & Development | 308.67M | 471.22M | 260.21M | 245.28M | 0.00 |
| General & Administrative | 338.28M | 433.18M | 356.53M | 303.37M | 0.00 |
| Selling & Marketing | 447.49M | 534.74M | 476.04M | 517.03M | 0.00 |
| SG&A | 785.77M | 967.92M | 832.57M | 820.39M | 0.00 |
| Other Expenses | 0.00 | 220.81M | 422.18M | 3.41M | 0.00 |
| Operating Expenses | 1.10B | 1.44B | 1.09B | 1.07B | 0.00 |
| Cost & Expenses | 3.84B | 5.42B | 4.38B | 4.02B | 0.00 |
| Interest Income | 113.44M | 25.64M | 2.03M | 4.44M | 7.26M |
| Interest Expense | 11.95M | 13.95M | 8.12M | 9.82M | 23.20M |
| Depreciation & Amortization | 231.80M | 231.54M | 220.13M | 235.23M | 0.00 |
| EBITDA | 1.19B | 4.68B | 2.76B | 2.13B | 1.07B |
| EBITDA Ratio | 24.80% | 48.62% | 42.52% | 36.12% | 0.00% |
| Operating Income | 967.96M | 4.45B | 2.54B | 1.90B | 0.00 |
| Operating Income Ratio | 20.14% | 46.22% | 39.13% | 32.14% | 0.00% |
| Total Other Income/Expenses | 359.87M | 228.08M | 416.55M | 2.11M | -77.59M |
| Income Before Tax | 1.33B | 4.37B | 2.51B | 1.98B | 0.00 |
| Income Before Tax Ratio | 27.62% | 45.38% | 38.68% | 33.60% | 0.00% |
| Income Tax Expense | 274.93M | 899.59M | 467.54M | 406.37M | 0.00 |
| Net Income | 1.02B | 3.38B | 1.97B | 1.52B | 0.00 |
| Net Income Ratio | 21.17% | 35.14% | 30.42% | 25.77% | 0.00% |
| EPS | 10.67 | 36.03 | 21.35 | 17.08 | 8.03 |
| EPS Diluted | 10.62 | 35.10 | 20.61 | 16.36 | 7.59 |
| Weighted Avg Shares Out | 95.33M | 93.88M | 92.52M | 89.08M | 82.63M |
| Weighted Avg Shares Out (Dil) | 95.77M | 96.39M | 95.90M | 93.20M | 87.83M |
Source: https://incomestatements.info
Category: Stock Reports